Enterobiotix raised about £19 million (US$25.7 million) to fund phase IIb development of EBX-102-02, a microbiome-based pill for irritable bowel syndrome with constipation (IBS-C). The company framed the round as support for late-stage execution and progression toward clinical proof points. The financing highlights continued investor appetite for microbiome therapeutics that can be delivered orally and evaluated through symptom-based endpoints common in gastroenterology trials. For sponsors, it also emphasizes how much of the current funding strategy is centered on getting to phase IIb readouts that can de-risk partnering or larger phase III programs. Investors will track whether EBX-102-02 can demonstrate durable symptom improvement and acceptable tolerability in a population where patient stratification can significantly affect trial outcomes.